Adoption of Universal Testing in Endometrial Cancers for Microsatellite Instability Using Next-Generation Sequencing. doi: 10.1200/PO.23.00033.

Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. doi: 10.1200/PO.23.00235.

Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. doi: 10.1001/jamaoncol.2023.3748.

Identification of fallopian tube microbiota and its association with ovarian cancer: a prospective study of intraoperative swab collections from 187 patients. doi: 10.1101/2023.06.28.23291999.

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCA-mutant ovarian cancer. doi: 10.1126/scitranslmed.add7872.

Sertoli-Leydig cell tumor associated with a germline DICER1 pathogenic variant diagnosed during pregnancy: Considerations for treatment, surveillance, and prevention. doi:10.1016/j.gore.2023.101215

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing. doi:10.1038/s41698-023-00379-8

Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays. doi:10.1200/PO.22.00720

TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol. doi:10.1136/ijgc-2023-004377

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. doi:10.1101/2023.03.20.23287465

What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women. doi: 10.1016/j.ygyno.2023.03.002.

Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10. doi: 10.1016/j.ebiom.2023.104477.

Participation of Patients With Limited English Proficiency in Gynecologic Oncology Clinical Trials. doi: 10.6004/jnccn.2022.7068.

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. doi: 10.1016/S1470-2045(22)00739-2.

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. doi: 10.1200/JCO.21.02947.

CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. doi: 10.1200/JCO.22.00430.